Xu M - Search Results

1

Albumin Binder-Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy.

Xu M, Zhang P, Ding J, Chen J, Huo L, Liu Z. Xu M, et al. J Nucl Med. 2022 Jun;63(6):952-958. doi: 10.2967/jnumed.121.262533. Epub 2021 Sep 30. J Nucl Med. 2022. PMID: 34593598 Free PMC article.

2

Activating TiO₂ Nanoparticles: Gallium-68 Serves as a High-Yield Photon Emitter for Cerenkov-Induced Photodynamic Therapy.

Duan D, Liu H, Xu Y, Han Y, Xu M, Zhang Z, Liu Z. Duan D, et al. Among authors: xu m, xu y. ACS Appl Mater Interfaces. 2018 Feb 14;10(6):5278-5286. doi: 10.1021/acsami.7b17902. Epub 2018 Feb 5. ACS Appl Mater Interfaces. 2018. PMID: 29368518

3

Preclinical Study of a Fully Human Anti-PD-L1 Antibody as a Theranostic Agent for Cancer Immunotherapy.

Xu M, Han Y, Liu G, Xu Y, Duan D, Liu H, Du F, Luo P, Liu Z. Xu M, et al. Among authors: xu y. Mol Pharm. 2018 Oct 1;15(10):4426-4433. doi: 10.1021/acs.molpharmaceut.8b00371. Epub 2018 Sep 4. Mol Pharm. 2018. PMID: 30133286

4

Size-Controlled Synthesis of Drug-Loaded Zeolitic Imidazolate Framework in Aqueous Solution and Size Effect on Their Cancer Theranostics in Vivo.

Duan D, Liu H, Xu M, Chen M, Han Y, Shi Y, Liu Z. Duan D, et al. Among authors: xu m. ACS Appl Mater Interfaces. 2018 Dec 12;10(49):42165-42174. doi: 10.1021/acsami.8b17660. Epub 2018 Nov 29. ACS Appl Mater Interfaces. 2018. PMID: 30457318

5

Side Chain Optimization Remarkably Enhances the in Vivo Stability of ¹⁸F-Labeled Glutamine for Tumor Imaging.

Chen J, Li C, Hong H, Liu H, Wang C, Xu M, Han Y, Liu Z. Chen J, et al. Among authors: xu m. Mol Pharm. 2019 Dec 2;16(12):5035-5041. doi: 10.1021/acs.molpharmaceut.9b00891. Epub 2019 Nov 12. Mol Pharm. 2019. PMID: 31670970

6

PET imaging facilitates antibody screening for synergistic radioimmunotherapy with a ¹⁷⁷Lu-labeled αPD-L1 antibody.

Ren J, Xu M, Chen J, Ding J, Wang P, Huo L, Li F, Liu Z. Ren J, et al. Among authors: xu m. Theranostics. 2021 Jan 1;11(1):304-315. doi: 10.7150/thno.45540. eCollection 2021. Theranostics. 2021. PMID: 33391476 Free PMC article.

7

Fatty acid-conjugated radiopharmaceuticals for fibroblast activation protein-targeted radiotherapy.

Zhang P, Xu M, Ding J, Chen J, Zhang T, Huo L, Liu Z. Zhang P, et al. Among authors: xu m. Eur J Nucl Med Mol Imaging. 2022 May;49(6):1985-1996. doi: 10.1007/s00259-021-05591-x. Epub 2021 Nov 8. Eur J Nucl Med Mol Imaging. 2022. PMID: 34746969

8

Production of positron-emitting radionuclide yttrium-86 with a computer-aided design target for positron emission tomography.

Chen J, Wang J, Xu M, Jia X, Song G, Liu Z. Chen J, et al. Among authors: xu m. Nucl Med Biol. 2022 May-Jun;108-109:54-60. doi: 10.1016/j.nucmedbio.2022.03.001. Epub 2022 Mar 10. Nucl Med Biol. 2022. PMID: 35305430

9

86Y-Labeled Albumin-Binding Fibroblast Activation Protein Inhibitor for Late-Time-Point Cancer Diagnosis.

Ding J, Xu M, Chen J, Zhang P, Huo L, Kong Z, Liu Z. Ding J, et al. Among authors: xu m. Mol Pharm. 2022 Sep 5;19(9):3429-3438. doi: 10.1021/acs.molpharmaceut.2c00579. Epub 2022 Aug 17. Mol Pharm. 2022. PMID: 35976352

10

Organotrifluoroborate enhances tumor targeting of fibroblast activation protein inhibitors for targeted radionuclide therapy.

Liu Y, Tang H, Song T, Xu M, Chen J, Cui XY, Han Y, Li Z, Liu Z. Liu Y, et al. Among authors: xu m. Eur J Nucl Med Mol Imaging. 2023 Jul;50(9):2636-2646. doi: 10.1007/s00259-023-06230-3. Epub 2023 Apr 27. Eur J Nucl Med Mol Imaging. 2023. PMID: 37103565

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

22,351 results

Search Page

Filters